Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, Takahashi H, Urabe F, Mori K, Tashiro K, Iwatani K, Shimomura T, Habuchi T, Kimura T.
Yanagisawa T, et al. Among authors: urabe f.
Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813. Online ahead of print.
Prostate. 2024.
PMID: 39417629